November 27-29 2018
Cambridge, MA, USA

 

Workshop A
Tuesday, November 27, 2018

08.00 - 11.00
Addressing the Complexities of Fibrosis Pathology in the Context of a Heterogeneous Pathology
Workshop Leader: Jeffrey Browning, Research Professor, Boston University Workshop Leader: Maria Trojanowska, Professor, Medicine, Boston University

Although the hypothesis of insult by inflammation preceding progressive fibrosis in diseases holds a lot of value, the specific aetiology and mechanisms of fibrosis manifesting in distinct organs remains uncertain. Coupled with inter individual variability, the challenges of running a successful clinical trial are significantly greater.
In this workshop, we will be:

  • Overviewing expert research on CD34-toCD90 transition work including discussion on other fibroblast states
  • Reviewing the heterogeneity in SSc populations, who is driving the fibrosis (e.g. activated fibroblasts vs myofibroblasts) and the ramifications for drug development
  • Discussing testing DMF in preclinical models and patient samples

Jeffrey Browning, Research Professor, Boston University

Maria Trojanowska, Professor, Medicine, Boston University

Workshop B
Tuesday, November 27, 2018

11.30 - 14.30
Prognostics, Therapeutics & Theranostics in Fibrosis
Workshop Leader: Rana Herro, Junior Faqculty Instructor, La Jolla Institute for Allergy & Immunology

With better screens and better tools giving better outcomes, critically assessing molecular prognostic biomarkers of fibrosis can inform an arsenal of non-invasive techniques and innovate drug development.

This workshop will explore:

  • Fibrosis, where does it start: the unmet need of prognostic markers to diagnose, stage disease severity, and segregate cohorts of patients.
  • Common pathways to different organ-specific fibrosis: Is there a central regulator of fibrosis across several organs we can target?
  • Combination therapies to treat fibrosis: How to improve therapeutics, specifically focusing on bi-functional molecules regulating both inflammation and fibrosis?
  • Screens for non-invasive theranostics, to monitor responses to targeted therapies

Rana Herro, Junior Faqculty Instructor, La Jolla Institute for Allergy & Immunology

Workshop C
Tuesday, November 27, 2018

15.00 - 18.00
Fibrosis as a Progenitor Disease
Workshop Leader: Michael Underhill, Professor, Department of Cellular & Physiological Sciences , University of British Columbia Workshop Leader: Fabio Rossi, Professor in Medical Genetics, University of British Columbia Workshop Leader: Dario Lemos, Instructor in Medicine (Harvard Medical School) and Associate Bioengineer (Brigham & Women's Hospital) ,

Fibrogenic cells are generated from tissue resident stromal progenitors. The transition between progenitors and fibrogenic cells is a potential therapeutic target as well as a mechanism whose study can reveal how fibrosis ensues and therefore how it can be prevented.

Key topics to be covered in this expert led session:

  • Origins of fibrogenic cells
  • Modeling human kidney fibrosis with hPSC-derived organoids
  • Mesenchymal progenitors in tissue regeneration and repair

Michael Underhill, Professor, Department of Cellular & Physiological Sciences , University of British Columbia

Fabio Rossi, Professor in Medical Genetics, University of British Columbia

Dario Lemos, Instructor in Medicine (Harvard Medical School) and Associate Bioengineer (Brigham & Women's Hospital) ,